Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pretomanid PK in Hepatic Impairment
NCT02422524Phase 1Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2018
- Primary completion
- Aug 2023
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pretomanid in Tuberculosis (TB) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Area Under the Concentration Time-curve Extrapolated to Infinity, Area Under the Concentration Time-curve to the Last Concentration and 5 more. Started Mar 2018; status: terminated.
02
Drugs
pretomanid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02422524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02422524.